Remove 2023 Remove Bioinformatics Remove Drug Development Remove Pharma Companies
article thumbnail

ADCs: the next generation of targeted therapies 

Drug Discovery World

Antibody drug conjugates (ADCs) are among the hottest properties in pharma, powerful anticancer drugs that target tumours and deliver a lethal payload that destroys them, while leaving healthy tissues untouched. He adds: “The rise of ADCs as a priority for big pharma companies can be attributed to several factors.

Therapies 162
article thumbnail

Open science, genomics, and the quiet revolution in our approach to pharma

Drug Discovery World

The tide has been turning in the worlds of diagnostics and drug development. Bioinformatics and genetic sequencing are starting to be placed front and centre of public research programmes as scientists from around the world recognise the substantial benefits of knowledge sharing and resource pooling when it comes to genetic science.

Science 130
article thumbnail

AI At The Frontier: Empowering Early Career Professionals In Drug Discovery

Elrig

Harini Srinivasan is a Principal Scientific Associate at Serna Bio with over 10 years of research experience in academic institutions, health care organizations and pharmaceutical companies. With a background in Bioinformatics and Computational Biology, she has a keen interest in using technology to solve problems in healthcare and medicine.